Themed with “cutting millions of new disability cases project”, China Stroke Conference was held in China National Convention Center in Beijing on May 14th- 16th, 2021. Professionals and scholars from home and abroad attended the conference and shared the accomplishments and best practice in stroke prevention and control across the international community. Neusoft, developer of the national level thrombolysis and thrombectomy platform eStroke, attended the Conference on invitation with its advanced intelligent diagnostic products and clinical solutions.
In order to continuously improve the technology for clinical diagnosis and treatment of stroke, Neusoft and the team led by Professor Ji Xunming, Vice President of Capital Medical University, Director of Standardization and Guidance Office for the “cutting millions of new disability cases project”, jointly launched eStroke National Thrombolysis and Thombectomy Imaging Platform 2.0 on the conference, lending substantive support to “the project”.
The National Thrombolysis and Thrombectomy Imaging Platform eStroke was jointly launched in 2018 by National Engineering Laboratory of Internet Medical Diagnosis and Treatment Technology of Xuanwu Hospital affiliated to Capital Medical University, Neusoft Intelligent Medical Research Institute and Neusoft Medical System Co., Ltd. It is designed to provide fast and accurate guidance for the early treatment of acute stroke, intravenous thrombolysis and intra-arterial thrombectomy. eStroke has three advantages. Firstly, it is compatible with multimodal imaging equipment, including multi-slice spiral CT scanner of more than 16 slice configurations and MRI scanner of more than 1.5T. Secondly, the whole process is automated, from scanning sequence to image post-processing and analysis, and imaging diagnostic report output. Thirdly, it is available for the research, development and engineering of technologies including remote and mobile emergency aid for cerebrovascular diseases, intelligent early warning and intervention for high-risk groups, combination treatment for cerebrovascular diseases, and virtual surgery.